Japanese scientists have commenced trials for a novel medication that holds the potential to enable humans to grow additional teeth. The development is being spearheaded by the startup Toregem BioPharma, and clinical studies are already underway with volunteer participants.
The core principle of the medication involves inhibiting a protein known as USAG-1, which normally limits further tooth formation. Researchers anticipate that by targeting this protein, they can stimulate dormant tooth buds and bypass the natural biological constraint that restricts tooth growth after the permanent set has developed.
The journey to this technology began with laboratory experiments. Researchers developed mice with a deactivated gene responsible for USAG-1’s function, which resulted in the animals developing extra teeth. Subsequently, similar tests were conducted on ferrets.
Since the close of 2024, clinical trials have been conducted at Kyoto University Hospital. The study involves 30 adult men who are missing at least one tooth. The primary objective of this current phase is to assess the safety of the new medication. However, specialists caution that participants in this research phase should not expect to see new teeth emerge.
Should the medication’s safety be validated, the subsequent stage will involve trials with children aged two to seven who have a congenital absence of teeth. Scientists estimate that this condition affects approximately one in a thousand individuals and can impede their ability to chew food effectively. Furthermore, adolescents with this diagnosis often experience psychological distress and social pressure.
Some independent experts suggest that even if new teeth successfully develop, they might erupt in incorrect positions. Nevertheless, the project’s creators believe that such issues can be addressed through conventional orthodontic treatments.
The final findings from the clinical studies have yet to be released. If the trials conclude successfully, Toregem BioPharma aims to bring the medication to market in the 2030s. Initially, it is planned for use in assisting children with congenital tooth agenesis, with future considerations for applying the technology to adult patients who have lost teeth due to injury or decay.
About the Author
